Cypress Funds Has Trimmed By $2.52 Million Its Valeant Pharmaceuticals Intl (Put) (VRX) Holding; Letko Brosseau & Associates Has Lowered Companhia De Saneamento Basi (SBS) Position

June 8, 2017 - By Vivian Park

Cypress Funds Llc decreased Valeant Pharmaceuticals Intl (Put) (VRX) stake by 40.91% reported in 2016Q4 SEC filing. Cypress Funds Llc sold 180,000 shares as Valeant Pharmaceuticals Intl (Put) (VRX)’s stock declined 15.71%. The Cypress Funds Llc holds 260,000 shares with $3.78 million value, down from 440,000 last quarter. Valeant Pharmaceuticals Intl (Put) now has $4.38B valuation. The stock declined 0.83% or $0.11 reaching $13.15 per share. About 31.61 million shares traded or 19.83% up from the average. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since June 8, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Letko Brosseau & Associates Inc decreased Companhia De Saneamento Basi (SBS) stake by 4.82% reported in 2016Q4 SEC filing. Letko Brosseau & Associates Inc sold 148,975 shares as Companhia De Saneamento Basi (SBS)’s stock declined 15.61%. The Letko Brosseau & Associates Inc holds 2.94M shares with $25.53 million value, down from 3.09M last quarter. Companhia De Saneamento Basi now has $6.23B valuation. The stock decreased 0.11% or $0.01 during the last trading session, reaching $9.11. About 1.22 million shares traded. Companhia de Saneamento Basico (ADR) (NYSE:SBS) has risen 24.02% since June 8, 2016 and is uptrending. It has outperformed by 7.32% the S&P500.

Among 24 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 5 have Buy rating, 3 Sell and 16 Hold. Therefore 21% are positive. Valeant Pharmaceuticals Intl had 95 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital with “Equal Weight” on Friday, February 10. Barclays Capital maintained the stock with “Equal Weight” rating in Thursday, May 11 report. JP Morgan maintained the shares of VRX in report on Thursday, April 20 with “Neutral” rating. IBC downgraded the shares of VRX in report on Tuesday, October 20 to “Sector Perform” rating. Mizuho maintained the shares of VRX in report on Tuesday, March 8 with “Neutral” rating. Morgan Stanley downgraded it to “Equal-Weight” rating and $17 target in Thursday, December 15 report. JP Morgan maintained it with “Overweight” rating and $225.0 target in Wednesday, November 11 report. Jefferies maintained the shares of VRX in report on Wednesday, March 16 with “Buy” rating. On Friday, October 9 the stock rating was initiated by Mizuho with “Neutral”. BMO Capital Markets downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, October 22 to “Market Perform” rating.

Investors sentiment decreased to 0.78 in Q4 2016. Its down 0.10, from 0.88 in 2016Q3. It dropped, as 82 investors sold VRX shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. 417,100 are held by Hutchin Hill Capital L P. Cibc Ww Mkts stated it has 3.59M shares. D E Shaw And Com owns 0.04% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1.66M shares. Riverpark Ltd Liability Company holds 14,995 shares. Marco Inv Mgmt holds 68,000 shares. State Of Wisconsin Invest Board reported 0.02% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Jefferies Group Limited Liability Com holds 98,574 shares or 0.01% of its portfolio. 194,900 were accumulated by Orbimed Advsr Ltd Liability Corp. Moreover, Apriem Advsrs has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Hexavest holds 0.07% or 264,677 shares. Old Mutual Customised Solutions (Proprietary) invested in 0.01% or 2,600 shares. Peak6 Invs LP has 68,715 shares for 0.01% of their portfolio. Balyasny Asset Mngmt Lc reported 1.49 million shares. Cmt Asset Mgmt holds 190,375 shares or 0.13% of its portfolio. Blackrock Incorporated invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Since December 12, 2016, it had 4 insider purchases, and 2 sales for $217.81 million activity. ValueAct Holdings – L.P. bought $32.47M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Tuesday, March 14. On Monday, December 12 Pershing Square Capital Management – L.P. sold $51.63 million worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) or 3.48M shares. Shares for $73,650 were bought by Ross Thomas W. Sr. on Wednesday, December 14. DE SCHUTTER RICHARD U had bought 20,000 shares worth $278,000 on Thursday, May 11. 24,000 shares were bought by Herendeen Paul, worth $257,280.